Latest news about Anlon Healthcare
Anlon Healthcare
14.28
-0.09(-0.63%)
Company Performance:
View Company Insights1D-0.63%
1M-4.80%
6M+18.90%
1Y+55.73%
5Y+55.73%
More news about Anlon Healthcare
05Aug 26
Anlon Healthcare targets 30% revenue CAGR, expands capacity to 1,600 MTPA
Anlon Healthcare Ltd reported a 133% YoY rise in PAT to ₹8.28 crore in Q1FY27, supported by a 163% increase in total income. The company's investor presentation highlights a strategic shift towards an integrated pharmaceutical platform with a target of 30% revenue CAGR over three years. Key initiatives include expanding capacity to 1,600 MTPA, filing new DMFs, and entering the Industrial & Fine Chemicals segment.
05Aug 26
Anlon Healthcare Latest Results: Targets 30% Revenue Growth Over Next Three Years
Anlon Healthcare expects 30% revenue growth over the next three years, driven by acquisitions, new product launches, and capacity expansion. The company's strategy combines inorganic growth through acquisitions with organic initiatives including new product development and increased production capacity. No specific quarterly financial metrics were provided in the source data.
02Aug 26
Anlon Healthcare Q1FY27 profit falls 51% sequentially to ₹4.8 crore
Anlon Healthcare’s Q1FY27 results show a standalone net profit of ₹479.71 lakh, reflecting a 35% YoY growth but a 51% sequential decline. Consolidated metrics reveal a significant expansion in revenue base to ₹8756.27 lakh, suggesting structural changes in reporting scope.
30Jul 26
Anlon Healthcare Q1 Results: Net Profit Rises to 48M Rupees YoY
Anlon Healthcare's Q1 results showed net profit rising to 48M rupees from 35M rupees YoY, while EBITDA improved to 75M rupees from 62M rupees. The EBITDA margin expanded to 24.08% from 18.73% on a year-on-year basis. Revenue, however, declined to 310M rupees compared to 333M rupees in the same quarter last year, indicating top-line pressure despite improved operational efficiency.
11Jul 26
Anlon Healthcare incorporates Anlon Biologics to expand biologics
Anlon Healthcare Ltd incorporated a new subsidiary, Anlon Biologics Private Limited, on July 10, 2026, to develop and manufacture peptides, biosimilars, and biological compositions. The subsidiary has an authorized and paid-up share capital of Rs. 1,000,000 and is yet to commence business operations. Anlon Healthcare holds a 65% stake in the entity, subscribing to 65,000 equity shares for an aggregate consideration of Rs. 650,000 via cash and banking channels.
07Jul 26
Anlon Healthcare CMD outlines growth strategy in interview
Anlon Healthcare Limited's Chairman & Managing Director, Mr. Punitkumar Rasadia, participated in an interview on July 06, 2026, to discuss business performance, industry outlook, and growth strategy. The interview covered operational updates, capital expenditure, acquisition possibilities, and financial guidance without sharing unpublished price sensitive information.
02Jul 26
Anlon Healthcare approves two new subsidiaries to expand portfolio
Anlon Healthcare Ltd approved the incorporation of two new subsidiaries, Anlon Medicare Private Limited and Anlon Biologics Private Limited, on July 1, 2026, with a total investment of ₹17.5 lakh. The company will hold a 55% stake in Anlon Medicare to manufacture surgical implants and a 65% stake in Anlon Biologics for peptides and biosimilars. Additionally, the Board approved renaming Remember India Health Links Private Limited to Anlon Medicos Private Limited, subject to regulatory approvals.
26Jun 26
Anlon Healthcare reports Q1FY26 net profit of ₹354.69 lakh
Anlon Healthcare reported a net profit of ₹354.69 lakh for Q1FY26 with revenue of ₹3,329.72 lakh. The board approved the unaudited results on November 11, 2025. Total assets increased to ₹19,775.76 lakh as of June 30, 2025.
12Jun 26
Anlon Healthcare CMD to discuss FY26 on NDTV Profit
Anlon Healthcare Limited announced that its Chairman & Managing Director, Mr. Punitkumar Rasadia, will appear on NDTV Profit on June 11, 2026, at 01:30 P.M. IST. The interview will cover the company's growth journey, recent developments, and financial performance for FY 2025-26. The company confirmed that no unpublished price-sensitive information will be shared.
10Jun 26
Anlon Healthcare FY26 PAT rises 42% to ₹29.09 crore
Anlon Healthcare reported a 42.98% YoY rise in consolidated total income to ₹172.22 crore for FY26, with PAT growing 41.77% to ₹29.09 crore. EBITDA increased 47.55% to ₹47.77 crore. The company completed acquisitions of Apiqo Organics and Bizotic Life Science, expanding capacity to 1400-1600 MTPA. Management guided for FY27 revenue of ₹380-400 crore and expects to be cash flow positive by FY27-end.
04Jun 26
Anlon Healthcare FY26 PAT rises 42% to ₹29.09 crore
Anlon Healthcare reported a 42.98% rise in consolidated total income to ₹172.22 crore for FY26, with net profit increasing to ₹29.09 crore. Q4FY26 total income stood at ₹50.90 crore. The company highlighted strategic acquisitions and capacity expansion in its investor presentation.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind Pharma
Dr Reddys Laboratories
Laurus Labs
Aurobindo Pharma
1,902.40
(-0.08%)
8,597.00
(+0.32%)
4,896.50
(-2.17%)
1,432.20
(-0.40%)
1,120.00
(+1.11%)
2,201.80
(+0.01%)
2,384.00
(-0.04%)
1,174.70
(-0.45%)
1,802.00
(-1.26%)
1,621.30
(+0.83%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
